

LINC00707 accelerates the proliferation, migration and invasion of clear cell renal cell carcinoma

L.-R. PANG¹, M.-X. HUANG¹, H. LI¹, G. CHEN², G.-P. ZHONG², B. YAO¹, J. CHEN¹

¹Department of Chemoradiotherapy Center, Yinzhou People's Hospital, Ningbo, China

²Department of Pathology, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Ningbo, China

Abstract. – **OBJECTIVE:** Long noncoding RNAs (lncRNAs) have been well concerned in tumor researches, which are believed to influence tumorigenesis and tumor progression. This study aims to uncover the role of LINC00707 in clear cell renal cell carcinoma (ccRCC) and the underlying mechanism.

MATERIALS AND METHODS: Differentially expressed lncRNAs in ccRCC tissues and renal epithelial tissues were analyzed in The Cancer Genome Atlas (TCGA), and LINC00707 was screened out. Expression level of LINC00707 in ccRCC cell lines was determined as well. Regulatory effects of LINC00707 on influencing proliferative, migratory, and invasive abilities of 786-O and 769-P cells were assessed. At last, relative levels of epithelial-mesenchymal transition (EMT)-related genes E-cadherin and N-cadherin in 786-O and 769-P cells were detected by quantitative real time-polymerase chain reaction (qRT-PCR) and Western blot.

RESULTS: LINC00707 was upregulated in ccRCC tissues and cell lines. Silence of LINC00707 attenuated proliferative, migratory, and invasive abilities of 786-O and 769-P cells. Moreover, knockdown of LINC00707 upregulated E-cadherin and downregulated N-cadherin in ccRCC cells at both mRNA and protein levels.

CONCLUSIONS: LINC00707 is upregulated in ccRCC, which could promote cancer cells to proliferate, migrate, and invade. LINC00707 accelerates the progression of ccRCC by activating EMT pathway.

Key Words:

CcRCC, LINC00707, Proliferation, Metastasis, EMT.

Introduction

Renal cell carcinoma (RCC) is the most common malignancy in the urinary system¹. Its incidence is on the rise annually, accounting for 5% of all malignancies in adults². Clear cell renal cell

carcinoma (ccRCC) is a prevalent subtype of RCC, ranks for 70-75% of all RCC cases³. Due to the lack of sensitivity diagnostic methods for early-stage ccRCC, about 20-30% of ccRCC patients are accompanied with distant metastasis at the initial diagnosis⁴. Surgical procedures are the golden standard for the treatment of local RCC. Nevertheless, nearly 20% local ccRCC patients experience post-operative recurrence. Meanwhile, ccRCC is not sensitive to chemotherapy and radiotherapy. Once the occurrence of lymphatic metastasis, the overall survival of metastatic ccRCC is usually within 5 years even performing the radical lymphadenectomy⁵. It is urgent to uncover the pathogenesis of ccRCC, so as to develop effective therapeutic targets for improving the clinical outcomes of ccRCC.

Long noncoding RNA (lncRNA) is a class of RNAs with more than 200 nucleotides that do not have a protein-encoding function. It has a similar structure to that of a mRNA^{6,7}. With the advance of the Human Genome Project, about 3% of human genome is identified to be able to encode proteins. The remaining are noncoding RNAs. In the past, lncRNAs were considered to be the by-products of transcription and did not have meaningful biological functions⁸. With the deepening of researches, lncRNAs are found to be closely related to the occurrence and development of various diseases, showing complex biological functions. Currently, lncRNAs are mainly divided into five categories, including antisense lncRNAs, intronic transcripts, large intergenic noncoding RNAs, promoter-associated lncRNAs, and UTR associated lncRNAs. It is reported that lncRNA HOTAIR could suppress gene transcription by binding to the methyltransferase family⁹. lncRNA PXN-AS1-L is resistant to RNA hydrolysis degradation or miRNA sponge by binding to mRNA¹⁰. LINC00707 is involved in many types of tumors, which is related to disease progno-

sis¹¹⁻¹³. This study mainly uncovered the biological role of LINC00707 in ccRCC.

Materials and Methods

Data Acquisition and Analysis

The Cancer Genome Atlas (TCGA) is a very important cancer database, containing clinical data, genomic variations, mRNA expressions, miRNA expressions, methylation, and other data of various types of human cancers. It is an excellent platform for cancer researches. Briefly, GDC TCGA Kidney Clear Cell Carcinoma (KIRC) containing genome-wide expression profile of ccRCC patients was downloaded from UCSC Xena platform (bioRxiv 326470; doi: <https://doi.org/10.1101/326470>) on ataseq.xenahubs.net. Expression data for LINC00707 expressions in 72 normal controls and 526 ccRCC tissues were obtained by searching for ENSG00000238266.

Cell Culture and Transfection

HK2, 786-O, ACHN, and 769-P cells were provided by American Type Culture Collection (ATCC; Manassas, VA, USA). They were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Gibco, Rockville, MD, USA) containing 10% fetal bovine serum (FBS; Gibco, Rockville, MD, USA) in an incubator with 5% CO₂ at 37°C.

Cells were pre-seeded in the 6-well plate with 60% confluence. Cell transfection was performed using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA). At 6 h, medium containing 10% FBS was replaced. Transfected cells for 24 h were harvested for other experiments. Sequences of transfection vectors were listed in Table I.

RNA Extraction and Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR)

Cells were lysed to harvest RNAs using TRIzol method (Invitrogen, Carlsbad, CA, USA), and the

extracted RNAs were subjected to reverse transcription according to the instructions of PrimeScript RT reagent Kit (TaKaRa, Otsu, Shiga, Japan). RNA concentration was detected using a spectrometer. QRT-PCR was then performed based on the instructions of SYBR Premix Ex TaqTM (TaKaRa, Otsu, Shiga, Japan) at 94°C for 5 min, and 40 cycles at 94°C for 30 s, 55°C for 30 s, and 72°C for 90 s. Relative level was calculated using the 2^{-ΔΔCt} method. Primer sequences were listed in Table I.

Cell Counting Kit-8 (CCK-8) Assay

Cells were seeded into 96-well plates with 2.0×10³ cells per well. At the appointed time points, 10 μL of CCK-8 solution (Dojindo Molecular Technologies, Kumamoto, Japan) was added in each well. The absorbance at 450 nm of each sample was measured by a microplate reader (Bio-Rad, Hercules, CA, USA).

5-Ethynyl-2'-Deoxyuridine (EdU) Assay

Cells were inoculated into 96-well plates with 2×10³ cells per well and labeled with 100 μL of EdU reagent (50 μM) per well for 2 h (R&D Systems, Minneapolis, MN, USA). After washing with phosphate-buffered saline (PBS), cells were fixed in 50 μL of fixation buffer, decolorized with 2 mg/mL glycine, and permeated with 100 μL of penetrant. After washing with PBS once, cells were stained with 4',6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich, St. Louis, MO, USA) in the dark for 30 min. EdU-positive ratio was determined under a fluorescent microscope.

Transwell

Cell density was adjusted to 1.5×10⁴ cells/mL. 100 μL of suspension was applied in the upper side of transwell chamber (Corning, Corning, NY, USA) coated with Matrigel. In the bottom side, 600 μL of medium containing 20% FBS was applied. After 48 h of incubation, cells penetrated

Table I. The list of primers and siRNA sequences.

Gene	Forward	Reverse
LINC00707	TCACATCTGTGAAAAGAGTGCT	CTGGACTGTGAGTACCAGGC
GAPDH	GGGAGCCAAAAGGGTCAT	GAGTCCTCCACGATACCAA
E-cadherin	GACAACAAGCCCGAATT	GGAAACTCTCTCGGTCCA
N-cadherin	CGGGTAATCTCCCAAATCA	CTTATCCCGGCGTTTCATC
siRNA sequences		
si-LINC00707	CAUGACGUGAGAACUACUAGAGAU	AUCUCUAGUAAGUUCUCACGUCAUG
si-NC	UUCUCCGAACGUGUCACGUTT	ACGUGACACGUUCGGAGAATT

to the bottom side were fixed in 4% paraformaldehyde for 20 min, stained with crystal violet for 20 min, and counted using a microscope. The number of penetrating cells was counted in 5 randomly selected fields per sample (magnification 200 \times).

Western Blot

Cells were lysed for extracting proteins using radioimmunoprecipitation assay (RIPA) and quantified by bicinchoninic acid (BCA) method (Beyotime, Shanghai, China). Protein sample was loaded for electrophoresis and transferred on a polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA, USA). After blocking in 5% skim milk for 2 h, membranes were subjected to incubation with primary and secondary antibodies. Bands were exposed by enhanced chemiluminescence (ECL) and analyzed by Image Software (NIH, Bethesda, MD, USA).

Statistical Analysis

Statistical Product and Service Solutions (SPSS) 22.0 (SPSS Inc. Chicago, IL, USA) and GraphPad prism 7 (GraphPad Software Inc., CA, USA) were used for data analysis. Data were expressed as

mean \pm standard deviation ($\bar{x} \pm SD$). Intergroup data were compared using the *t*-test. $p < 0.05$ considered the difference was statistically significant.

Results

Upregulated LINC00707 In CcRCC

A dataset containing LINC00707 expressions in 72 normal controls and 526 ccRCC tissues was downloaded from UCSC Xena in TCGA. LINC00707 was found to be remarkably upregulated in ccRCC tissues relative to normal ones (Figure 1A). After screening the data, a total of 70 paired ccRCC tissues and matched paracancerous tissues were harvested. Identically, LINC00707 was highly expressed in ccRCC tissues relative to controls (Figure 1B). *In vitro* level of LINC00707 remained higher in RCC cells relative to renal tubular epithelial cells (Figure 1C). To further uncover the biological role of LINC00707, we first constructed si-LINC00707 and tested its transfection efficacy. LINC00707 was markedly downregulated by transfection of si-LINC00707 in 786-O and 769-P cells (Figure 1D, 1E). The




Figure 1. Upregulated LINC00707 in ccRCC. **A**, LINC00707 expressions in 72 normal controls and 526 ccRCC tissues downloaded from UCSC Xena in TCGA. **B**, Relative level of LINC00707 in paired ccRCC tissues and matched paracancerous tissues. **C**, Relative level of LINC00707 in HK2, 786-O, ACHN and 769-P cells. **D**, Transfection efficacy of si-LINC00707 in 786-O cells. **E**, Transfection efficacy of si-LINC00707 in 769-P cells.




Figure 2. Knockdown of LINC00707 suppressed the proliferative ability of ccRCC. **A**, EdU-labeled, DAPI-stained and merged images of 786-O cells transfected with si-NC or si-LINC00707 (magnification: 400 \times). **B**, EdU-labeled, DAPI-stained and merged images of 769-P cells transfected with si-NC or si-LINC00707 (magnification: 400 \times). **C**, Percentage of EdU-positive cells in 786-O and 769-P cells transfected with si-NC or si-LINC00707. **D**, Viability in 786-O cells transfected with si-NC or si-LINC00707. **E**, Viability in 769-P cells transfected with si-NC or si-LINC00707.

above data suggested that LINC00707 may exert a crucial role in the progression of ccRCC.

Knockdown of LINC00707 Suppressed the Proliferative Ability of CcRCC

After transfection of si-LINC00707 in 786-O and 769-P cells, EdU-positive ratio was remarkably declined, suggesting the attenuated proliferative ability (Figure 2A-2C). Moreover, CCK-8 assay revealed the reduced viability in 786-O and 769-P cells transfected with si-LINC00707 relative to those transfected with si-NC (Figure 2D, 2E). As a result, silence of LINC00707 remarkably attenuated proliferative ability of ccRCC.

Knockdown of LINC00707 Suppressed the Metastatic Abilities of ccRCC

Potential influences of LINC00707 on the metastatic abilities of ccRCC were assessed by performing transwell assay. Migrative cell number was markedly reduced after transfection of

si-LINC00707 in 786-O and 769-P cells (Figure 3A, 3B). Meanwhile, the invasive cell number was also reduced by silence of LINC00707 (Figure 3C, 3D). LINC00707 was proved to accelerate ccRCC to migrate and invade.

LINC00707 Activated EMT Pathway in ccRCC

EMT was first discovered in embryonic development. Later, EMT occurrence is discovered after the injury of adult epidermal cells. In the occurrence and progression of tumors, EMT leads to loss of epithelium characteristics and gain of mesenchymal cell phenotypes, thereafter, enhancing the metastatic capacities¹⁴. The process of EMT is regulated by a series of related transcription factors, most notably the downregulated E-cadherin, Cytokeratin, ZO-1, and upregulated N-cadherin, Vimentin, Snail1, Snail2, Twist, MMP-2, etc.^{15,16}. Here, we determined expression levels of E-cadherin and N-cadherin in ccRCC.




Figure 3. Knockdown of LINC00707 suppressed the migratory and invasive abilities of ccRCC. **A**, Migration in 786-O and 769-P cells transfected with si-NC or si-LINC00707 (magnification: 40 \times). **B**, Migrative cell number in 786-O and 769-P cells transfected with si-NC or si-LINC00707. **C**, Invasion in 786-O and 769-P cells transfected with si-NC or si-LINC00707 (magnification: 40 \times). **D**, Invasive cell number in 786-O and 769-P cells transfected with si-NC or si-LINC00707

Silence of LINC00707 upregulated the mRNA level of E-cadherin and downregulated N-cadherin in 786-O and 769-P cells (Figure 4A, 4B). Similar results were yielded at their protein levels (Figure 4C, 4D). It is suggested that LINC00707 was capable of activating EMT pathway, thus aggravating the progression of ccRCC.

Discussion

LncRNA exerts an important role in tumor development. It is widely involved in tumor epigenetics, signaling pathway regulation and their interactive regulation as skeleton, guiding, decoy, and signaling molecules. Abnormally expressed lncRNAs are of significance in different stages of tumor progression. They are capable of regulating cellular behaviors of tumor cells. It is reported that LINC00707 stimulates the proliferation and metastasis of gastric cancer by interacting with the mRNA stabilizing protein HuR¹³. In liver cancer, LINC00707 sponges miR-206 to upregulate CDK14, thus aggravating the disease progres-

sion¹⁷. By absorbing miR-370-3p to upregulate WNT2B, LINC00707 accelerates the osteogenesis of bone marrow mesenchymal stem cells¹⁸. In this paper, LINC00707 was upregulated in ccRCC tissues and cell lines. Silence of LINC00707 inhibited ccRCC to proliferate, migrate, and invade.

Epithelial-mesenchymal transition (EMT) is the biological process where epithelial cells are transformed into cells with mesenchymal phenotype. EMT is vital in embryonic development, chronic inflammation, tissue remodeling, cancer metastasis, and various fibrotic diseases. Its main features include downregulation of cell adhesion molecules (such as E-cadherin), cytoskeletal transformation from cytokeratin to vimentin, and the occurrence of morphological characteristics of mesenchymal cells. EMT leads to the losses of cell polarity and attachment to the basement membrane, thus enhancing the metastatic ability. It is a necessary process for tumor cells obtaining higher capacities of migration and invasiveness. To elucidate the molecular mechanism of EMT in malignant tumor cells contributes to develop therapeutic targets alleviating tumor metastasis.




Figure 4. LINC00707 activated EMT pathway in ccRCC. **A**, mRNA levels of E-cadherin and N-cadherin in 786-O cells transfected with si-NC or si-LINC00707. **B**, mRNA levels of E-cadherin and N-cadherin in 769-P cells transfected with si-NC or si-LINC00707. **C**, Protein levels of E-cadherin and N-cadherin in 786-O cells transfected with si-NC or si-LINC00707. **D**, Protein levels of E-cadherin and N-cadherin in 769-P cells transfected with si-NC or si-LINC00707.

LncRNAs are identified to mediate EMT in tumors. For example, lncRNA OTUD6B-AS1, which is highly expressed in ccRCC, can inhibit the expressions of EMT-related proteins *via* Wnt/ β -catenin¹⁹. LncRNA ATB promotes EMT of breast cancer by sponging miR-200c²⁰. Up-regulated LINC01296 in pancreatic ductal adenocarcinoma indicates a poor prognosis and promotes cell metastasis by affecting EMT²¹. We showed that knockdown of LINC00707 upregulated E-cadherin and downregulated N-cadherin in ccRCC cells at both mRNA and protein levels. It is indicated that LINC00707 accelerated the progression of ccRCC by activating EMT pathway. However, we failed to clarify the molecular mechanism of LINC00707 in influencing the EMT of ccRCC, which requires further explorations.

Conclusions

This study showed that LINC00707 is upregulated in ccRCC, which could promote cancer cells to proliferate, migrate, and invade. LINC00707 accelerates the progression of ccRCC by activating EMT pathway. LINC00707 may be a novel hallmark for predicting the progression of ccRCC.

Funding Acknowledgements

This study was supported by Beijing Medical and Health Welfare Funding (No. F2168G).

Conflict of Interests

The authors declare that they have no conflict of interests.

References

- 1) RINI BI, CAMPBELL SC, ESCUDIER B. Renal cell carcinoma. *Lancet* 2009; 373: 1119-1132.
- 2) SIEGEL RL, MILLER KD, JEMAL A. *Cancer Statistics, 2017. CA Cancer J Clin* 2017; 67: 7-30.
- 3) NICKERSON ML, JAEGER E, SHI Y, DUROCHER JA, MAHURKAR S, ZARIDZE D, MATVEEV V, JANOUT V, KOLLAROVA H, BENCKO V, NAVRATILOVA M, SZESZENIA-DABROWSKA N, MATES D, MUKERIA A, HOLCATOVA I, SCHMIDT LS, TORO JR, KARAMI S, HUNG R, GERARD GF, LINEHAN WM, MERINO M, ZBAR B, BOFFETTA P, BRENNAN P, ROTHMAN N, CHOW WH, WALDMAN FM, MOORE LE. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. *Clin Cancer Res* 2008; 14: 4726-4734.
- 4) ESCUDIER B, PORTA C, SCHMIDINGER M, RIOUX-LECLERCO N, BEX A, KHOO V, GRUENVALD V, HORWICH A. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2016; 27: v58-v68.
- 5) HSIEH JJ, PURDUE MP, SIGNORETTI S, SWANTON C, ALBIGES L, SCHMIDINGER M, HENG DY, LARKIN J, FICARRA V. Renal cell carcinoma. *Nat Rev Dis Primers* 2017; 3: 17009.
- 6) HU X, SOOD AK, DANG CV, ZHANG L. The role of long noncoding RNAs in cancer: the dark matter matters. *Curr Opin Genet Dev* 2018; 48: 8-15.
- 7) HONG O, LI O, ZHENG W, XIAO WZ, ZHANG L, WU D, CAI GY, HE JC, CHEN XM. LncRNA HOTAIR regulates HIF-1alpha/AXL signaling through inhibition of miR-217 in renal cell carcinoma. *Cell Death Dis* 2017; 8: e2772.
- 8) LIU D, LI Y, LUO G, XIAO X, TAO D, WU X, WANG M, HUANG C, WANG L, ZENG F, JIANG G. LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. *Cancer Lett* 2017; 388: 281-291.
- 9) KALWA M, HANZELMANN S, OTTO S, KUO CC, FRANZEN J, JOUSSEN S, FERNANDEZ-REBOLLO E, RATH B, KOCH C, HOFMANN A, LEE SH, TESCHENDORFF AE, DENECKE B, LIN Q, WIDSCHWENDTER M, WEINHOLD E, COSTA IG, WAGNER W. The lncRNA HOTAIR impacts on mesenchymal stem cells via triple helix formation. *Nucleic Acids Res* 2016; 44: 10631-10643.
- 10) YUAN JH, LIU XN, WANG TT, PAN W, TAO QF, ZHOU WP, WANG F, SUN SH. The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1. *Nat Cell Biol* 2017; 19: 820-832.
- 11) MA T, MA H, ZOU Z, HE X, LIU Y, SHUAI Y, XIE M, ZHANG Z. The long intergenic noncoding RNA 00707 promotes lung adenocarcinoma cell proliferation and migration by regulating Cdc42. *Cell Physiol Biochem* 2018; 45: 1566-1580.
- 12) WANG J, LUO Z, YAO T, LI W, PU J. LINC00707 promotes hepatocellular carcinoma progression through activating ERK/JNK/AKT pathway signaling pathway. *J Cell Physiol* 2019; 234: 6908-6916.
- 13) XIE M, MA T, XUE J, MA H, SUN M, ZHANG Z, LIU M, LIU Y, JU S, WANG Z, DE W. The long intergenic non-protein coding RNA 707 promotes proliferation and metastasis of gastric cancer by interacting with mRNA stabilizing protein HuR. *Cancer Lett* 2019; 443: 67-79.
- 14) DIEPENBRUCK M, CHRISTOFORI G. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? *Curr Opin Cell Biol* 2016; 43: 7-13.
- 15) TIWARI N, GHELDOLF A, TATARI M, CHRISTOFORI G. EMT as the ultimate survival mechanism of cancer cells. *Semin Cancer Biol* 2012; 22: 194-207.
- 16) PEINADO H, CANO A. New potential therapeutic targets to combat epithelial tumor invasion. *Clin Transl Oncol* 2006; 8: 851-857.
- 17) TU J, ZHAO Z, XU M, CHEN M, WENG Q, WANG J, JI J. LINC00707 contributes to hepatocellular carcinoma progression via sponging miR-206 to increase CDK14. *J Cell Physiol* 2019; 234: 10615-10624.
- 18) JIA B, WANG Z, SUN X, CHEN J, ZHAO J, QIU X. Long noncoding RNA LINC00707 sponges miR-370-3p to promote osteogenesis of human bone marrow-derived mesenchymal stem cells through upregulating WNT2B. *Stem Cell Res Ther* 2019; 10: 67.
- 19) WANG G, ZHANG ZJ, JIAN WG, LIU PH, XUE W, WANG TD, MENG YY, YUAN C, LI HM, YU YP, LIU ZX, WU Q, ZHANG DM, ZHANG C. Novel long noncoding RNA OTUD6B-AS1 indicates poor prognosis and inhibits clear cell renal cell carcinoma proliferation via the Wnt/beta-catenin signaling pathway. *Mol Cancer* 2019; 18: 15.
- 20) LI RH, CHEN M, LIU J, SHAO CC, GUO CP, WEI XL, LI YC, HUANG WH, ZHANG GJ. Long noncoding RNA ATB promotes the epithelial-mesenchymal transition by upregulating the miR-200c/Twist1 axis and predicts poor prognosis in breast cancer. *Cell Death Dis* 2018; 9: 1171.
- 21) YUAN Q, ZHANG Y, FENG L, JIANG Y. Upregulated long noncoding RNA LINC01296 indicates a dismal prognosis for pancreatic ductal adenocarcinoma and promotes cell metastatic properties by affecting EMT. *J Cell Biochem* 2019; 120: 552-561.